Monday, June 2, 2025
News PouroverAI
Visit PourOver.AI
No Result
View All Result
  • Home
  • AI Tech
  • Business
  • Blockchain
  • Data Science & ML
  • Cloud & Programming
  • Automation
  • Front-Tech
  • Marketing
  • Home
  • AI Tech
  • Business
  • Blockchain
  • Data Science & ML
  • Cloud & Programming
  • Automation
  • Front-Tech
  • Marketing
News PouroverAI
No Result
View All Result

Revolution Medicines: A Big Pipeline In Need Of Big Data (NASDAQ:RVMD)

September 25, 2023
in Business
Reading Time: 4 mins read
0 0
A A
0
Share on FacebookShare on Twitter


Tara Moore

Topline Abstract

Revolution Medicines, Inc. (NASDAQ:RVMD) burst onto the scene with an IPO again in early 2020, they usually’ve fairly nicely held floor on a multi-billion-dollar valuation for nearly 4 years. Whereas they’ve an especially diversified pipeline of medication focusing on a who’s-who of classical signaling molecules, they’re nonetheless doing numerous feeling round for his or her large flagship pipeline venture, they usually’re doing so at large expense. Although they’ve defied bearish predictions to this point, it is nonetheless a really excessive danger, comparatively low reward proposition to take a position right now. Let me inform you why.

Pipeline Overview

RMC-4630

RVMD made its splash a couple of years in the past with one of many first inhibitors of a phosphatase referred to as SHP2 to be moved towards scientific trials. This drug candidate is named RMC-4630, and it confirmed some early promise in preclinical work and in an early scientific readout of RAS-addicted cancers. Including RMC-4630 to the KRAS G12C inhibitor sotorasib confirmed modest response charges in sufferers with beforehand handled, KRAS G12C-positive non-small cell lung most cancers, as nicely.

Whereas RMC-4630 has moved furthest in RVMD’s pipeline, it additionally has probably the most questions. Following a reappraisal by accomplice Sanofi, their developmental partnership was severed, and now per the corporate’s newest steerage, any additional improvement of this SHP2 inhibitor might be determined primarily based on a whole readout of their ongoing RMC-4630-03 examine. Of their newest earnings name, RVMD all however distanced themselves completely from their authentic pipeline, together with RMC-4630, in favor of pursuing various KRAS therapies.

RAS(ON) inhibitors

RVMD has moved decisively towards the event of so-called “RAS(ON)” inhibitors. This refers to brokers that preferentially inhibit the lively type of KRAS, versus the primary era of KRAS inhibitors (sotorasib and adagrasib) that bind to the inactive kind, so-called “RAS(OFF)” inhibitors. That is achieved by first binding a chaperone protein referred to as cyclophilin A, after which forming a triplet complicated together with lively KRAS, blocking its motion on different molecules within the cell.

RVMD has a complete suite of various KRAS inhibitors, together with RMC-6291, RMC-9805, RMC-0708, and RMC-8839, which goal particular types of mutant KRAS (G12C, G12D, Q61H, and G13C, respectively). They’re additionally working enthusiastically on RMC-6236, which has been proven in preclinical research to have the ability to block any mutation of KRAS, in addition to wildtype protein.

At present, RVMD are guiding that we are able to anticipate scientific information for his or her G12C drug (RMC-6291) and the pan-RAS inhibitor (RMC-6236) later this 12 months, together with findings that this 12 months’s AACR-NCI-EORTC Worldwide Convention on Molecular Targets and Most cancers Therapeutics going down October 7-10.

Whereas these tasks are younger, the potential may be very excessive right here. Focusing on KRAS G12C by itself represented a giant accomplishment for oncology. It is taken over 30 years to reach at an lively drug obtainable for sufferers to focus on this molecule, and sotorasib and adagrasib are restricted solely to this very particular kind. Far more widespread mutations like G12D stay untouched, and that is essential for illnesses like colorectal most cancers and pancreatic most cancers.

Whereas it is early days nonetheless, there’s rather a lot to be excited for right here.

Monetary Overview

Per RVMD’s Q2 2023 earnings report, the corporate held $380 million in money and equivalents and $529 million in marketable securities, with whole present property reaching $922 million. This was up from $660 million in This fall 2022, owing largely to a $300 million infusion of money from a public inventory providing again in March 2023.

One other large latest occasion for RVMD was the acquisition of EQRx, Inc. (EQRX) in an all-stock transaction that may deliver into play EQRX



Source link

Tags: BigdataMedicinesNASDAQRVMDPipelineRevolution
Previous Post

Canadian union Unifor names GM its second bargaining target among Detroit Three By Reuters

Next Post

Li Auto shares sink as Huawei enters EV space By Investing.com

Related Posts

Can You Guess What Percentage Of Their Wealth The Rich Keep In Cash?
Business

Can You Guess What Percentage Of Their Wealth The Rich Keep In Cash?

June 10, 2024
UGRO Capital: Targeting to hit milestone of Rs 20,000 cr loan book in 8-10 quarters: Shachindra Nath
Business

UGRO Capital: Targeting to hit milestone of Rs 20,000 cr loan book in 8-10 quarters: Shachindra Nath

June 10, 2024
Blinken set to arrive in Egypt for Gaza ceasefire push By Reuters
Business

Blinken set to arrive in Egypt for Gaza ceasefire push By Reuters

June 10, 2024
Volvo is moving EV production from China to Belgium as the EU eyes tariffs on Beijing
Business

Volvo is moving EV production from China to Belgium as the EU eyes tariffs on Beijing

June 9, 2024
France’s Macron calls for snap election after losing big to the far right in EU vote
Business

France’s Macron calls for snap election after losing big to the far right in EU vote

June 9, 2024
Upgrades for Best Buy and Lululemon By Investing.com
Business

Upgrades for Best Buy and Lululemon By Investing.com

June 9, 2024
Next Post
Li Auto shares sink as Huawei enters EV space By Investing.com

Li Auto shares sink as Huawei enters EV space By Investing.com

Amazon invests up to $4 billion in AI startup Anthropic, intensifying cloud tech competition By Investing.com

Amazon invests up to $4 billion in AI startup Anthropic, intensifying cloud tech competition By Investing.com

Red Hat and Oracle bring Red Hat OpenShift to Oracle Cloud Infrastructure

Red Hat and Oracle bring Red Hat OpenShift to Oracle Cloud Infrastructure

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • Trending
  • Comments
  • Latest
Is C.AI Down? Here Is What To Do Now

Is C.AI Down? Here Is What To Do Now

January 10, 2024
Accenture creates a regulatory document authoring solution using AWS generative AI services

Accenture creates a regulatory document authoring solution using AWS generative AI services

February 6, 2024
Managing PDFs in Node.js with pdf-lib

Managing PDFs in Node.js with pdf-lib

November 16, 2023
23 Plagiarism Facts and Statistics to Analyze Latest Trends

23 Plagiarism Facts and Statistics to Analyze Latest Trends

June 4, 2024
NVIDIA’s Marketing Strategy Case Study

NVIDIA’s Marketing Strategy Case Study

October 25, 2023
The Ultimate Guide to Google Ads [Examples]

The Ultimate Guide to Google Ads [Examples]

March 14, 2024
Can You Guess What Percentage Of Their Wealth The Rich Keep In Cash?

Can You Guess What Percentage Of Their Wealth The Rich Keep In Cash?

June 10, 2024
AI Compared: Which Assistant Is the Best?

AI Compared: Which Assistant Is the Best?

June 10, 2024
How insurance companies can use synthetic data to fight bias

How insurance companies can use synthetic data to fight bias

June 10, 2024
5 SLA metrics you should be monitoring

5 SLA metrics you should be monitoring

June 10, 2024
From Low-Level to High-Level Tasks: Scaling Fine-Tuning with the ANDROIDCONTROL Dataset

From Low-Level to High-Level Tasks: Scaling Fine-Tuning with the ANDROIDCONTROL Dataset

June 10, 2024
UGRO Capital: Targeting to hit milestone of Rs 20,000 cr loan book in 8-10 quarters: Shachindra Nath

UGRO Capital: Targeting to hit milestone of Rs 20,000 cr loan book in 8-10 quarters: Shachindra Nath

June 10, 2024
Facebook Twitter LinkedIn Pinterest RSS
News PouroverAI

The latest news and updates about the AI Technology and Latest Tech Updates around the world... PouroverAI keeps you in the loop.

CATEGORIES

  • AI Technology
  • Automation
  • Blockchain
  • Business
  • Cloud & Programming
  • Data Science & ML
  • Digital Marketing
  • Front-Tech
  • Uncategorized

SITEMAP

  • Disclaimer
  • Privacy Policy
  • DMCA
  • Cookie Privacy Policy
  • Terms and Conditions
  • Contact us

Copyright © 2023 PouroverAI News.
PouroverAI News

No Result
View All Result
  • Home
  • AI Tech
  • Business
  • Blockchain
  • Data Science & ML
  • Cloud & Programming
  • Automation
  • Front-Tech
  • Marketing

Copyright © 2023 PouroverAI News.
PouroverAI News

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In